Choi Youn Baik
Department of Surgery, Chung Hospital, Seoul, Korea.
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Endocrinol Metab (Seoul). 2016 Dec;31(4):525-532. doi: 10.3803/EnM.2016.31.4.525. Epub 2016 Nov 4.
Bariatric surgery is considered to be the most effective treatment modality in maintaining long-term weight reduction and improving obesity-related conditions in morbidly obese patients. In Korea, surgery for morbid obesity was laparoscopic sleeve gastrectomy first performed in 2003. Since 2003, the annual number of bariatric surgeries has markedly increased, including adjustable gastric banding (AGB), Roux-en-Y gastric bypass, sleeve gastrectomy, mini-gastric bypass, and others. In Korea, AGB is much more common than in others countries. A large proportion of doctors, the public, and government misunderstand the necessity and effectiveness of bariatric surgery, believing that bariatric surgery has an unacceptably high morbidity, and that it is not superior to non-surgical treatments to improve obesity and obesity-related diseases. The effectiveness, safety, and cost-effectiveness of bariatric surgery have been well demonstrated. The Korean Society of Metabolic and Bariatric Surgery recommend bariatric surgery confining to morbidly obese patients (body mass index ≥40 or >35 in the presence of significant comorbidities).
减重手术被认为是维持病态肥胖患者长期体重减轻及改善肥胖相关病症的最有效治疗方式。在韩国，2003年首次开展了腹腔镜袖状胃切除术用于治疗病态肥胖。自2003年以来，减重手术的年手术量显著增加，包括可调节胃束带术（AGB）、Roux-en-Y胃旁路术、袖状胃切除术、迷你胃旁路术等。在韩国，AGB比其他国家更为常见。很大一部分医生、公众和政府误解了减重手术的必要性和有效性，认为减重手术的发病率高得令人难以接受，且在改善肥胖及肥胖相关疾病方面并不优于非手术治疗。减重手术的有效性、安全性和成本效益已得到充分证明。韩国代谢与减重外科学会建议减重手术仅适用于病态肥胖患者（体重指数≥40或存在严重合并症时>35）。
